These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16625092)

  • 1. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
    Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
    Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
    Ordóñez NG
    Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
    Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
    Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary adenocarcinoma simulating malignant mesothelioma.
    Tang P; Vatsia SK; Teichberg S; Kahn E
    Arch Pathol Lab Med; 2001 Dec; 125(12):1598-600. PubMed ID: 11735699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.
    Kambara T; Amatya VJ; Kushitani K; Suzuki R; Fujii Y; Kai Y; Miyata Y; Okada M; Takeshima Y
    Am J Surg Pathol; 2020 Sep; 44(9):1259-1265. PubMed ID: 32496433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
    Brown RW; Clark GM; Tandon AK; Allred DC
    Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal lamina reduplication in malignant epithelioid pleural mesothelioma.
    Di Muzio M; Spoletini L; Strizzi L; Procopio A; Tassi G; Casalini A; Modesti A
    Ultrastruct Pathol; 1998; 22(6):467-75. PubMed ID: 9891926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary pleural epithelioid mesothelioma of clear cell type: a case report and review of current literature.
    Gkogkou C; Samitas K; Foteinou M
    Ultrastruct Pathol; 2011 Dec; 35(6):267-70. PubMed ID: 21978187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
    King JE; Thatcher N; Pickering CA; Hasleton PS
    Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
    Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melan A (A103) is not a marker of mesothelioma.
    Ordóñez NG; Shen SS; Zenali M; Deavers MT
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
    Peralta Soler A; Knudsen KA; Jaurand MC; Johnson KR; Wheelock MJ; Klein-Szanto AJ; Salazar H
    Hum Pathol; 1995 Dec; 26(12):1363-9. PubMed ID: 8522310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusual clear cell variant of epithelioid mesothelioma.
    Dessy E; Falleni M; Braidotti P; Del Curto B; Panigalli T; Pietra GG
    Arch Pathol Lab Med; 2001 Dec; 125(12):1588-90. PubMed ID: 11735696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
    Comin CE; Saieva C; Messerini L
    Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.
    Soini Y; Kinnula V; Kahlos K; Pääkkö P
    J Clin Pathol; 2006 Mar; 59(3):250-4. PubMed ID: 16505274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.